PATENT CLAIM ANALYSIS

Application Number: 16226605
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "252180"]

Abstract:
Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Claim (Index 64):
A method for treating a hematological cancer in a subject in need thereof, the method comprising:\n administering an effective amount of a compound having the following structure: or a pharmaceutically acceptable salt thereof, to the subject.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.59322
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14776392', '13940641', '12922122', '16033038', '15598540']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7311342930479816
- 35 USC 102 Novelty (BERT): 0.5649388918441793
- Combined Prediction Score: 0.7145147529276014
- Mean Citation Score: 257.013164
- Max Citation Score: 384.77478
- Similarity Product: 342.4204220533705

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test